Lasa Supergenerics Ltd.
Snapshot View

48.70 +1.30 ▲2.7%

20 May 2022, 11:55:15 AM
Volume: 19,217

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lasalabs.com
Market Cap 192.59 Cr.
Enterprise Value(EV) 174.78 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) -1.32 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-03
Industry PE 28.47 Trailing Twelve Months Ending 2022-03
Book Value / Share 36.54 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.30 Calculated using Price: 47.35
Dividend Yield 0.53 Period Ending 2021-03
No. of Shares Subscribed 4.07 Cr. 40,672,668 Shares
FaceValue 10
Company Profile

Lasa Supergenerics (Lasa) is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012. The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecules-from discovery research up to full-scale bulk production.

Lasa group’s marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The group has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations.

Business area of the company

The company is specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India

Product Categories

  • Veterinary API Products
  • Other API Products
  • Animal Feed Ingredients
  • Reagents For Therapeutic Use


Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.74%
1 Week
+4.73%
1 Month
-17.39%
3 Month
-2.50%
6 Month
-20.36%
1 Year
-37.84%
2 Year
+53.39%
5 Year
10 Year
6 years 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 8.65 14.33 -10.81 2.94 15.17
Return on Capital Employed (%) 14.45 12.80 -3.73 6.77 17.14
Return on Assets (%) 2.07 4.79 -4.44 1.50 10.43

Balance Sheet View Details

Particulars 7 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 0 75 117 105 141 159 149
Non Curr. Liab. 0 83 62 43 11 8 7
Curr. Liab. 70 107 107 76 41 44
Minority Int.
Equity & Liab. 0 228 287 255 229 208 199
Non Curr. Assets 149 178 170 153 144 127
Curr. Assets 0 79 109 86 76 64 72
Misc. Exp. not W/O 0
Total Assets 0 228 287 255 229 208 199

Profit Loss View Details

Particulars 7 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 199 244 170 167 202 137
Other Income 2 3 1 0 0 0
Total Income 201 247 170 167 203 137
Total Expenditure -153 -202 -159 -137 -155 -121
PBIDT 48 45 12 30 47 16
Interest -12 -11 -8 -8 -2 0
Depreciation -8 -18 -19 -17 -16 -14
Taxation 0 -3 4 -1 -7 1
Exceptional Items -26 -8
PAT 2 12 -12 4 23 -5
Adjusted EPS 472 5 -5 1 6 -1

Cash Flow View Details

Particulars 6 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 -3 40 41 14 41
Cash Fr. Inv. 0 -44 -7 -2 -4
Cash Fr. Finan. 0 0 4 -33 -10 -36
Net Change 0 -3 0 0 2 1
Cash & Cash Eqvt 0 0 1 0 3 4

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 64.47 64.47 64.47 64.47 64.47 64.47 64.47 45.01 43.78
Public 35.53 35.53 35.53 35.53 35.53 35.53 35.53 54.99 56.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.23 35.15

Announcements View Details

Wed, 27 Apr 2022
Press Release
Lasa Supergenerics Limited has informed the Exchange about press release dated 26-Apr-2022 titled ¬タワLASA SECURES BULK ORDER OF ¬ツᄍ 500 MILLION
Tue, 26 Apr 2022
Press Release
Lasa Supergenerics Limited has informed the Exchange about press release dated 26-Apr-2022 titled ¬タワLASA SECURES BULK ORDER OF ¬ツᄍ 500 MILLION
Tue, 26 Apr 2022
Related Party Transaction
Lasa Supergenerics Limited has informed the Exchange about related party transaction for the period ended March 2022

Technical Scans View Details

Thu, 19 May 2022
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 212,197.18 913.00 +3.2%
Divi's Laboratories Ltd. 111,510.08 4,319.00 +2.8%
Cipla Ltd. 75,683.19 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. 65,571.78 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. 52,245.59 3,641.00 +0.2%
Gland Pharma Ltd. 51,277.11 3,052.00 -1.5%
Piramal Enterprises Ltd. 45,274.50 1,925.25 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 32.93 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-12 43.43 4,319.00 +2.8%
Cipla Ltd. Consolidated 2022-03 30.07 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 30.04 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.10 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-12 43.23 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-12 36.44 1,925.25 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.11 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-12 10.30 4,319.00 +2.8%
Cipla Ltd. Consolidated 2022-03 3.63 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.41 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.44 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-12 7.47 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-12 1.28 1,925.25 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,319.00 +2.8%
Cipla Ltd. Consolidated 2021-03 0.10 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,925.25 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,319.00 +2.8%
Cipla Ltd. Consolidated 2021-03 14.13 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,925.25 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,319.00 +2.8%
Cipla Ltd. Consolidated 2021-03 14.13 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,925.25 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,319.00 +2.8%
Cipla Ltd. Consolidated 2021-03 19,159.59 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,925.25 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 913.00 +3.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,319.00 +2.8%
Cipla Ltd. Consolidated 2021-03 2,401.30 975.05 +4.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,208.95 +7.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,641.00 +0.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,052.00 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,925.25 +1.6%